Association between immune-related adverse events and survival in patients with renal cell carcinoma treated with nivolumab plus ipilimumab: immortal time bias-corrected analysis-Reference-Cited by-同舟云学术

Association between immune-related adverse events and survival in patients with renal cell carcinoma treated with nivolumab plus ipilimumab: immortal time bias-corrected analysis

Published:2023-09-02 Issue:12 Volume:28 Page:1651-1658
ISSN:1341-9625
Container-title:International Journal of Clinical Oncology
language:en
Short-container-title:Int J Clin Oncol

Author:

Washino Satoshi,Shirotake Suguru,Takeshita Hideki,Inoue Masaharu,Miura Yuji,Hyodo Yoji,Kagawa Makoto,Izumi Keita,Oyama Masafumi,Kawakami Satoru,Saito Kazutaka,Matsuoka Yoh,Taniuchi Satsuki,Shintani Ayumi,Miyagawa Tomoaki

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology,General Medicine,Surgery

Link

https://link.springer.com/content/pdf/10.1007/s10147-023-02406-x.pdf

Reference30 articles.

1. Motzer RJ, Tannir NM, McDermott DF et al (2018) Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 378:1277–1290

2. Francisco LM, Sage PT, Sharpe AH (2010) The PD-1 pathway in tolerance and autoimmunity. Immunol Rev 236:219–242

3. Friedman CF, Proverbs-Singh TA, Postow MA (2016) Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA Oncol 2:1346–1353

4. Maughan BL, Bailey E, Gill DM et al (2017) Incidence of immune-related adverse events with program death receptor-1-and program death receptor-1 ligand-directed therapies in genitourinary cancers. Front Oncol 7:56

5. Chan KK, Bass AR (2020) Autoimmune complications of immunotherapy: pathophysiology and management. BMJ 369:m736

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The incidence of immune-related adverse events (irAEs) and their association with clinical outcomes in advanced renal cell carcinoma and urothelial carcinoma patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis;Cancer Treatment Reviews;2024-09

2. Prognostic significance of inflammatory markers in patients with advanced renal cell carcinoma receiving nivolumab plus ipilimumab;International Journal of Clinical Oncology;2024-07-24

4. The correlation between immune-related adverse events and efficacy of immune checkpoint inhibitors;Japanese Journal of Clinical Oncology;2024-05-20

5. Pre-existing Autoimmune Diseases and Immune Checkpoint Inhibitors for Cancer Treatment: Considerations About Initiation, Flares, Immune-Related Adverse Events, and Cancer Progression;Rheumatic Disease Clinics of North America;2024-05